# US 2021/0330689 A1 · Composition for treating blood cancer using 4'-thio-5-aza-2'-deoxycytidine and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330689 A1
- Document ID: US20210330689A1
- Status: Published application
- Kind: A1
- Application number: 17/238,182
- Filed: 2021-04-22
- Published: 2021-10-28
- Earliest claimed: 2020-04-23
- Assignees: Southern Research Institute; Pinotbio, Inc.
- Applicants: Southern Research Institute; PinotBio, Inc.
- Inventors: Mark J. Suto; Rebecca Boohaker; Doo Young Jung; Jin Soo Lee; Hyunyong Cho
- Web page: https://patentgrep.com/patent/US20210330689A1

## CPC

- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to pharmaceutical compositions for treating blood cancer, which includes 4′-thio-5-aza-2′-deoxycytidine (Aza-T-dCyd), and methods of treating blood cancer using a composition for oral administration that includes Aza-T-dCyd. The present invention provides a significant blood cancer therapeutic effect without having toxicity in a blood cancer mouse model or a human even with the Aza-T-dCyd dose conventionally known to have toxicity. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

## Claims

### Claim 1

A pharmaceutical composition comprising a therapeutically effective amount of a compound having a structure:
and a pharmaceutically acceptable carrier,
wherein the therapeutically effective amount is of from about 5 mg/m2 to no more than about 70 mg/m2, and
wherein the pharmaceutical composition is formulated for oral administration.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the therapeutically effective amount is of from about 5 mg/m2 to no more than about 10 mg/m2.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the therapeutically effective amount is of from about 35 mg/m2 to no more than about 55 mg/m2.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the therapeutically effective amount is of from about 55 mg/m2 to no more than about 66 mg/m2.

### Claim 5

A method of treating a blood cancer in a human subject in need thereof, the method comprising administering to the subject an effective amount of a compound having a structure:
wherein the effective amount is of from about 5 mg/m2 to no more than about 70 mg/m2 per 24 hour time period, thereby treating the blood cancer in the subject.

### Claim 6 (depends on 5)

The method of claim 5, wherein the effective amount is of from about 5 mg/m2 to no more than about 10 mg/m2 per 24 hour time period.

### Claim 7 (depends on 5)

The method of claim 5, wherein the effective amount is of from about 35 mg/m2 to no more than about 55 mg/m2 per 24 hour time period.

### Claim 8 (depends on 5)

The method of claim 5, wherein the effective amount is of from about 55 mg/m2 to no more than about 66 mg/m2 per 24 hour time period.

### Claim 9 (depends on 5)

The method of claim 5, wherein the effective amount is administered in a single dose.

### Claim 10 (depends on 5)

The method of claim 5, wherein the effective amount is administered via a plurality of doses.

### Claim 11 (depends on 5)

The method of claim 5, wherein administering is repeated administration.

### Claim 12 (depends on 11)

The method of claim 11, wherein administering is for a time period of from about 4 days to about 6 days.

### Claim 13 (depends on 5)

The method of claim 5, wherein administering is via a course of treatment comprising:
(a) a first treatment cycle that includes administering the effective amount of the compound for a time period of from about 4 days to about 6 days;
(b) a first rest period that includes abstaining from administering the compound for a time period of from about 1 day to about 3 days;
(c) a second treatment cycle that includes administering the effective amount of the compound for a time period of from about 4 days to about 6 days; and
(d) a second rest period that includes abstaining from administering the compound for a time period of at least about 8 days.

### Claim 14 (depends on 13)

The method of claim 13, wherein the effective amount is administered in a single dose.

### Claim 15 (depends on 13)

The method of claim 13, wherein the effective amount is administered via a plurality of doses.

### Claim 16 (depends on 13)

The method of claim 13, wherein the effective amount is administered via a single dose on some days and via a plurality of doses on other days.

### Claim 17 (depends on 5)

The method of claim 5, wherein administering is via a course of treatment comprising:
(a) a first treatment cycle that includes administering the effective amount of the compound once per day for a time period of about 5 days;
(b) a first rest period that includes abstaining from administering the compound for a time period of about 2 days;
(c) a second treatment cycle that includes administering the effective amount of the compound once per day for a time period of about 5 days; and
(d) a second rest period that includes abstaining from administering the compound for a time period of at least about 9 days.

### Claim 18 (depends on 5)

The method of claim 5, wherein the blood cancer is non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma, leukemia, lymphoma, myelodysplastic syndrome, acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, or solitary myeloma.

### Claim 19 (depends on 1)

A kit comprising an effective amount of the pharmaceutical composition of claim 1, and one or more of:
(a) at least one agent associated with the treatment of a disorder of uncontrolled cellular proliferation;
(b) instructions for administering the composition in connection with treating a disorder of uncontrolled cellular proliferation; and
(c) instructions for treating a disorder of uncontrolled cellular proliferation.

### Claim 20 (depends on 19)

The kit of claim 19, wherein the agent is a chemotherapeutic agent.
